Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 811 results for "novartis ag"

BioLineRX boosted by liver disease drug acquisition
Globes

BioLineRX boosted by liver disease drug acquisition

BioLineRX will develop the drug up to the human clinical trial stage under its collaboration agreement with Novartis. The share price of drug development company BioLineRX (Nasdaq/TASE: BLRX) rose 22% yesterday, although it has fallen back 2.4% ... Globes, 19 hours ago
[x]  

77 images for novartis ag

Live Trading News, 1 day ago
Live Trading News, 1 day ago
Octafinance, 1 week ago
Bidness Etc, 3 weeks ago
NewsMax.com, 1 week ago
Bidness Etc, 1 month ago
Nasdaq, 2 weeks ago
Bloomberg, 2 weeks ago
SRN News, 3 weeks ago
Nasdaq, 3 weeks ago

Novartis AG (NVS) Position Raised by Confluence Investment Management LLC

Confluence Investment Management LLC boosted its stake in shares of Novartis AG (NYSE:NVS) by 11.7% during the second quarter, Holdings Channel reports. The fund owned 106,371 shares of the company's stock after buying an additional 11,121 shares ...
 Zolmax News13 hours ago Argyle Capital Management Inc. Has $766,000 Position in Novartis AG (NVS)  Zolmax News13 hours ago Novartis AG (NVS) Stake Maintained by Mraz Amerine & Associates Inc.  WKRB News15 hours ago Novartis AG (NVS) Shares Bought by LS Investment Advisors LLC  Mideast Time1 day ago
[x]  
Live Trading News

Novartis AG (ADR) (NYSE:NVS) Heffx Trading Outlook

Overall, the bias in prices is: Upwards. Short term: Prices are stalling. Intermediate term: Prices are ranging. The projected upper bound is: 83.51. The projected lower bound is: 79.43. The projected closing price is: 81.47. ...
 Live Trading News1 day ago Novartis AG (NYSE:NVS)'s Assigned ABR Rating Of 2.26  Markets Daily15 hours ago Does Novartis AG (NVS) Have The Solution For Malaria?  InsiderMonkey.com4 days ago Analysts Set Expectations for Novartis AG's FY2017 Earnings (NVS)  American Banking News4 days ago
[x]  

Novartis A Buy At Chardan

Chardan Capital's Gbola Amusa believes Novartis AG (ADR) (NYSE: NVS ) has the potential for excess shareholder returns over the long-term by generating shared value for society through performance on 1) disruptive or sustainable innovation, 2) ...
 Yahoo! Finance6 days ago
PharmaVOICE

Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions

Today 11:51 AM ET (Thomson Reuters ONE) Print Novartis International AG / . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. - Ilaris(R) (canakinumab) is the first ...
 TD Ameritrade3 days ago Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients  SPi World News4 days ago Novartis gets Indian patent for skin cancer drug Tafinlar  Financial Express6 days ago NOVARTIS : Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs  4 Traders5 days ago
[x]  

Media Advisory - Novartis employees come together for annual Ride for Life

Novartis employees close in on the finish line from a 600km bike ride in support of the Canadian Breast Cancer Foundation DORVAL, QC , Sept. 20, 2016 /CNW/ -Twelve years and going strong, a group of 40 dedicated employees from Novartis Canada ...
 Canada NewsWire6 days ago

Avis aux médias - La campagne annuelle Roule pour la vie de Novartis est de retour

Des employés terminent leur périple à vélo de 600km au profit de la Fondation canadienne du cancer du sein DORVAL, QC , le 20sept. 2016 /CNW/ -Pour une douzième année, la tradition se poursuit: 40courageux employés de Novartis ayant ...
 Canada NewsWire6 days ago
Zacks.com

Novartis Ilaris Approved for Extended Use in Periodic Fever

Switzerland-based Novartis AG NVS announced that its arthritis drug, Ilaris, was approved in the U.S. for expanded use in the treatment of three distinct types of periodic fever syndromes tumor necrosis factor-receptor associated periodic syndrome ...
 Zacks.com1 day ago
[x]  
MyNewsDesk

Global Vaccines Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Sanofi Pasteur, NOVARTIS, Glaxosmithkline - Research and Markets

DUBLIN--(Business Wire)--Research and Markets has announced the addition of the "Global Vaccines Market Analysis 2016 - Forecast to 2022" report to their offering. This report analyzes the global markets for "Vaccines Market". The market ...
 Digital Journal1 week ago Global Leiomyosarcoma Pipeline Review, H2 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Novartis, Pfizer, Vicore Pharam - Research and Markets  PharmiWeb1 week ago Systemic Antibiotic-Sulfonamide Combination Pharmaceuticals Market - Emerging Trends and Forecast 2016-2023  Digital Journal23 hours ago Prescription Pharmaceuticals Market Worth USD 918.74 Billion by 2020, at a CAGR of 4.8%  Digital Journal1 day ago
[x]  
Nasdaq

Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study

Novartis AG NVS announced positive top-line data from a phase III study (ASCEND-4) on its oncology drug, Zykadia, for the treatment of patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). We expect ...
 Yahoo! Singapore3 days ago Armed With Fresh Phase III Data, Novartis AG Eyes First-Line Use for Lung Cancer Drug Zykadia  BioSpace4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - novartis ag
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less